Brooklyn Investment Group Has $69,000 Stake in Jazz Pharmaceuticals PLC $JAZZ

Brooklyn Investment Group lifted its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 411.1% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 552 shares of the specialty pharmaceutical company’s stock after buying an additional 444 shares during the quarter. Brooklyn Investment Group’s holdings in Jazz Pharmaceuticals were worth $69,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Hurley Capital LLC acquired a new stake in Jazz Pharmaceuticals in the 1st quarter valued at $25,000. Elequin Capital LP raised its stake in shares of Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock worth $26,000 after purchasing an additional 183 shares during the period. Parallel Advisors LLC raised its stake in shares of Jazz Pharmaceuticals by 85.6% during the 1st quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company’s stock worth $32,000 after purchasing an additional 119 shares during the period. Picton Mahoney Asset Management raised its stake in Jazz Pharmaceuticals by 2,445.5% in the 1st quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock valued at $34,000 after acquiring an additional 269 shares during the period. Finally, Spire Wealth Management raised its stake in Jazz Pharmaceuticals by 137.6% in the 1st quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company’s stock valued at $35,000 after acquiring an additional 161 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Trading Up 2.1%

Jazz Pharmaceuticals stock opened at $123.11 on Friday. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $148.06. The stock has a market capitalization of $7.47 billion, a PE ratio of -18.29, a price-to-earnings-growth ratio of 7.60 and a beta of 0.34. The business’s fifty day moving average is $112.73 and its 200 day moving average is $117.15.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.05 billion. During the same period last year, the business earned $5.30 earnings per share. The company’s quarterly revenue was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, sell-side analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total value of $107,630.00. Following the transaction, the chief executive officer owned 436,973 shares of the company’s stock, valued at approximately $47,031,403.99. This represents a 0.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.30% of the company’s stock.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of a number of recent analyst reports. Zacks Research raised Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, August 15th. Piper Sandler reaffirmed an “overweight” rating and issued a $147.00 target price (down previously from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Morgan Stanley cut their target price on Jazz Pharmaceuticals from $165.00 to $162.00 and set an “overweight” rating for the company in a research note on Wednesday, August 6th. Royal Bank Of Canada lowered their price objective on Jazz Pharmaceuticals from $182.00 to $172.00 and set an “outperform” rating for the company in a research report on Wednesday, May 7th. Finally, Wall Street Zen downgraded Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, May 15th. Thirteen equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $181.43.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.